Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Homo sapiens | flap structure-specific endonuclease 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | exonuclease, putative | flap structure-specific endonuclease 1 | 380 aa | 322 aa | 24.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | flap structure-specific endonuclease 1, putative | 0.0031 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.6637 | 0.6637 |
Echinococcus multilocularis | flap endonuclease 1 | 0.0031 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trichomonas vaginalis | flap endonuclease-1, putative | 0.0031 | 1 | 1 |
Loa Loa (eye worm) | flap endonuclease-1 | 0.0031 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0016 | 0.365 | 0.365 |
Leishmania major | flap endonuclease-1 (FEN-1), putative | 0.0031 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.6637 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0016 | 0.365 | 0.365 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0.6637 | 0.6637 |
Plasmodium vivax | flap endonuclease 1, putative | 0.0031 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.6637 | 0.6637 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 0.6637 | 0.7583 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.6637 | 0.6637 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.6637 | 1 |
Trypanosoma brucei | unspecified product | 0.0016 | 0.365 | 0.365 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma cruzi | flap endonuclease-1 (FEN-1), putative | 0.0031 | 1 | 1 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.6637 | 0.6637 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0.6637 | 0.6637 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.6637 | 0.5 |
Giardia lamblia | Flap structure-specific endonuclease | 0.0031 | 1 | 1 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.6637 | 0.7583 |
Plasmodium falciparum | flap endonuclease 1 | 0.0031 | 1 | 1 |
Entamoeba histolytica | Flap nuclease, putative | 0.0031 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | unspecified product | 0.0016 | 0.365 | 0.365 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.6637 | 0.5 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.6637 | 0.7583 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | flap endonuclease-1 (FEN-1), putative | 0.0031 | 1 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.6637 | 0.6637 |
Schistosoma mansoni | flap endonuclease-1 | 0.0028 | 0.8752 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.6637 | 0.6637 |
Echinococcus granulosus | flap endonuclease 1 | 0.0031 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0016 | 0.365 | 0.365 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.6637 | 0.6637 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.6637 | 0.6637 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 8.9125 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.